Good afternoon, my name Good afternoon. My name is Ala, and I will be your conference operator today. At this time, I would like to welcome everyone to the Jabil Second Quarter Earnings Call. All lines have been placed on mute to prevent any background noise. After the speakers' remarks, there will be a question-and-answer session. [Operator Instructions] Thank you. Beth Walters, Senior Vice President of Communications and Investor Relations, you may begin your conference.

Thank you very much. Welcome to our second quarter and fiscal year 2018 earnings call. Joining me today on the call are CEO, Mark Mondello; and our Chief Financial Officer, Forbes Alexander. This call is being recorded and will be posted for audio playback on the Jabil website, jabil.com, in the Investors section. Our second quarter press release, slides and corresponding webcast links are also available on our website. In these materials, you will find the financial information that we will cover during this conference call. We ask that you follow our presentation the slides on the website beginning with Slide 2, our forward-looking statements. During this conference call, we will be making forward-looking statements, including those regarding the anticipated outlook for our business, our currently expected third quarter of fiscal 2018 net revenue and earnings results, the financial performance of the company and our long-term outlook for the company. These statements are based on current expectations, forecasts and assumptions involving risks and uncertainties that could cause actual outcomes and results to differ materially. An extensive list of these risks and uncertainties are identified in our Annual Report on Form 10-K for the fiscal year ended August 31, 2017, on subsequent reports on Form 10-Q and Form 8-K and our other securities filings. Jabil disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. Today's call will begin with Mark with his comments on our results and outlook for the business in fiscal 2018. Forbes will follow with comments on our second fiscal quarter results and guidance for our third quarter of 2018. Following our prepared remarks, we will open it up to questions from call attendees. I'll now turn the call over to Mark.

Thanks, Beth. Good afternoon. As always, I appreciate everyone taking time to join our call today. I'll begin by extending my sincere gratitude to each and every employee here at Jabil for making safety their personal priority. Thanks for your care and commitment. Now let's take a look at our second quarter results. I'm pleased with the quarter and the strong start to fiscal 2018. Our team delivered $179 million in core operating income on revenues of $5.3 billion, resulting in core earnings per share of $0.66. Add to this the fact that Jabil's cash flows and earnings are becoming more diversified and less dependent on any single product or product family for that matter, a definitive proof point that our strategy is taking hold. Another item that stands out for me when I think about the quarter is the fact that revenue overshot the midpoint of our guidance by $400 million, while at the same time, core earnings per share came in $0.04 above the midpoint of our guidance range, largely driven by a favorable tax rate. So why didn't we see additional margin dollars tied to the higher levels of revenue? Let me try and explain. The additional $400 million of revenue was driven by the abrupt acceleration of three near term market share wins inside of our EMS segment, combined with stronger than expected volumes in our Green Point sector. As for the missing margin dollars, this was based on intra-quarter investments we made in our EMS business based on the strength of the business itself, combined with cost overruns in our packaging business, as the team navigated tough challenges within the quarter, challenges that are common when faced with healthy growth. As customary, Forbes will provide detail around the results during his prepared remarks. I'd now…

Thank you, Mark. And good afternoon, everyone. I'd ask you to turn to Slide three where I'll review our second quarter fiscal 2018 results. Net revenue for the quarter was $5.3 billion, growth of 19% on a year-over-year basis. GAAP operating income is $130 million with GAAP net income of $37 million. GAAP net diluted earnings per share were $0.21 for the quarter. Core operating income was $179 million with core earnings per share of $0.66. Turning to Slide 4 in our segment discussion. In the second quarter, revenue from our Diversified Manufacturing Services segment was $2.4 billion, an increase of 38% on a year-over-year basis, slight [ph] in growth in programs within our mobility and lifestyles and health care businesses. This represented 46% of total company revenue. And operating income for the quarter was 3.4%. Our Electronics Manufacturing services segment revenue was $2.9 billion, an increase of 7% on a year-over-year basis, reflecting growth across capital equipment, industrial energy and automotive customers and represented 54% of total company revenue. Operating income for this segment was 3.3%. I'd now like to briefly turn - to update you on our restructuring alignment plan. This plan continues to remain on track, and during the quarter, we recorded approximately $5 million associated with this activity. We anticipate conclusion of this plan and charges of approximately $30 million in the second half of fiscal 2018. As a reminder, this plan will result in an incremental cost savings benefit of $20 million to $30 million in fiscal 2019. I'd now like to address the recent tax reform. We do not currently expect any significant impact to our core effective tax rate from the enactment of the new U.S. Tax Act. However, in the second quarter, we did record in GAAP earnings a provisional tax expense…

Thank you, Mark and Forbes. Before we begin the question-and-answer session, I'd like to remind our call participants that at the request of our customers, and as usual, we will not address any customer or product-specific questions. And we thank you in advance for your cooperation. Operator, we're ready to begin the Q&A session.

[Operator Instructions] Our first question comes from the line of Adam Tindle [Raymond James]. Your line is open.

Okay, thanks. And good afternoon. Mark, you alluded to investments in EMS, which is muting some of the normal operating leverage that we might see. Can you help us quantify this in any way? And should this attenuate to allow fiscal '19 EMS operating margin to get back to or above fiscal 2017 levels?

Adam, well, first off, I think, on the EMS margins themselves, I still feel very good about where we'll end up in fiscal '18 for EMS margins. In terms of the investments we're making, it's widespread, but if I had to take a stab, areas like automotive, Industrial & Energy probably stand out in that group more than any other. But again, the EMS business in total serves, I don't know, 200-or-so customers. So it's spread pretty evenly across the mix. I would say that we made the investments, Adam, based on the fact that early on in the quarter there was good indications that the business was going to be quite strong. So some of this is nothing more than maybe investments we are looking at more towards the back half of the year that we accelerated.

Okay, it makes sense. And Mark, you completed one board meeting. I think you've got another one upcoming. You've been diversifying cash flows, while still returning cash to shareholders. And just hoping you can talk about how you and the board are thinking about a capital allocation framework at this point. Does it make sense to accelerate diversification through more organic investments? And how do you balance this versus returning cash to shareholders? Thanks.

Yes. So I love our capital allocation at the moment. I think it's very reflective of the strength of the cash flows of the business. We as a leadership team, and certainly, in conjunction with our board, talk about that often. I think about the last couple of years returning $1 billion to shareholders, making very, very thoughtful organic investments in then what largely has been a bunch of tuck-in acquisitions. And I think sometimes the tuck-in acquisitions we do get lost and because they're small. And we do, I don't know, half a dozen of those a year. But I think those tuck-in acquisitions over the last 18 months have been pretty vital in both the revenue growth as well as the margins in both divisions, but certainly the EMS segment. In terms of - we've been pretty muted on, well, the capital returns to shareholders extend beyond this fiscal year, we'll take that up. We recognize that. We'll take it up with our board in April and probably have more to say about that in the June call.

Fair enough. Thanks a lot.

Yeah.

Our next question comes from the line of Matt Sheerin [Stifel]. Your line is open.

Yes, thanks. And thank for taking the question. Just, again, regarding the DMS segment. You've had some nice profitability growth year-over-year. If you look at the guidance, assuming that the Nypro Healthcare business grows sequentially sort of trying to back into the Green Point number, it looks like it'll be down, I don't know, 30% to 40%. And you've had the cyclical or these quarter-to-quarter swings, obviously, in the May quarter in the past. In terms of profitability, and if you're still targeting sort of that 4% EBIT or operating margin for the EMS segment, it looks like you're still going to be at least modestly profitable in DMS for the May quarter. Is that a good way to think about it?

I think it's a great way to think about it. The May quarter, if you if you assume that we're having rationale participation in our Green Point business, widespread in Green Point, as well as mobility, for the last number of years, 3Q has always been a heavy investment quarter in that part of our business. It's still a heavy investment quarter. But if you think about our guide, you think about where we set you in terms of revenue levels, you think about EMS margins kind of on an annual basis being very similar to '17, I think you back into the fact that DMS in terms of absolute profit dollars will be much better and larger than they were in 3Q, 2017.

Okay. Thanks, Mark. That's helpful. And on your commentary regarding some hiccups with the packaging business, obviously, due to very strong growth there. Are those issues that have been resolved and in terms of the profitability contribution from Nypro/healthcare to DMS, do you expect that to continue to grow in terms of its contribution?

Yes. So for me, it's nothing that has me flustered whatsoever. The packaging business is growing. There's a lot of moving parts. It's a complicated business, but it's a business I like a lot. To sit here and say all the issues have been resolved, I would say, many of the issues have been resolved as we move into 4Q and into '19, I expect all issues to be resolved.

Okay. Thanks very much.

Yeah.

Our next question comes from the line of Mark Delaney [Goldman Sachs]. Your line is open.

Yes, good afternoon. Thanks for taking the questions. First question was a follow-up to the comments, Mark, you made about DMS and your expectations for fiscal '19. I think you said you expect some more stability in your DMS segment next fiscal year, but maybe trade-off slightly lower margin. Any quantification or better detail you can provide us on that deal?

Sure, Mark. Yes. So I think the comment I made around DMS applies to the whole company. I think you start to get a theme here. So I love the vast majority of all of our business in DMS, whether it be healthcare packaging or what we're doing today in Green Point. I think the comment I made in my prepared remarks is that across the entire enterprise, Mark, we are looking to drive more and more diversification and cash flows and earnings. I think that's for a couple of simple reasons. Number one is we're just not smart enough as a management team to figure out all the puts and takes and what technologies and hardware products and everything else are going to win and lose across the globe today. The other comment I made is we're making some positions inside of our Green Point business where I would rather take stronger diversification versus reliance on some single selected product families. And based on the diversification there, based on the higher material content on a product by-product basis, some of the product blended margins may be a bit lower. But I think what we end up within the end markets, if we get that right, is we end up with a DMS business with both Green Point, healthcare and packaging where we get just a higher level of fixed asset utilization throughout the year. We don't get quite as bad. And we're doing that in such a way that we've got certain parts of the overall DMS business that's just growing at faster rates than others. So as I look to fiscal '19 and beyond, I really like the outlook for the DMS sector as well, along with DMS. So I kind of look at '19 going you know, if we get a few things going our way, I think it's going to be a nice year.

That's helpful. A follow-up question for fiscal '18 outlook. You talked about areas a number of areas, especially in EMS, that are driving upside versus prior views. Any areas or markets that you thought as being weaker? And help better understanding you can help us with in terms of, you know, in the past, when the markets softened, oftentimes there's a couple of quarters where things continued to go softer. Just how you'll be able to think about in terms of the guidance for this year and if, in fact, any end markets are weaker than last quarter? Thanks.

Yes, Mark. So I think, again, I think I'd answer it this way. The - I just it's hard to comprehend just how broad-based EMS is. It's just it's a business that cuts across, again, so many different brands, so many different customers, so many different products. If I had to characterize again where we're seeing strength, industrial energy, semi-cap equipment, auto, and then it's got a bit of tail to it. In terms of where we're seeing weakness, touch wood right now, we're not seeing any weakness in really any part of the business. And again, think that's reflective in the revenue numbers. If you take a look at fiscal year '17, I think, on EMS, DMS segment, we did about $11 billion. And I think if you kind of extrapolate out our 3Q guidance and the annual guidance, you'll get a feel that at the beginning of the year, we thought EMS revenue might be up 3.5%, 4%, and it can vary well be double that. So - and I think what's interesting is there might be some markets we serve in EMS where the markets themselves may be a little bit weak. But what's ironic in that right now is we're actually picking up decent amount of share gains in those markets. So all in all, I feel pretty good about what we're looking at with EMS. And again, this is coming off of a fiscal year '17 where the team drove margins to record highs coming off of '16 where they delivered, I don't remember the exact number, but roughly 3.5% up margins. So I'd like the story there quite a bit.

Thank you very much.

Yeah.

The next question comes from the line of Sean Hannan [Needham & Company]. Your line is open.

Yeah. Good evening. Thanks for taking the question here. So Mark and Forbes and team, just want to see if I could get a little bit more information on the Nypro business at this point. So you folks certainly entered the year with your pretty good growth expectations. We're starting to see some of that. Was hoping maybe we can get some granularity as we separate the path of what's occurring related to health care versus packaging. How does that materialize here for as we move through '18? And what are some thoughts on how that could continue in '19? Because I believe that the growth expectations remain fairly healthy for next year as well? Thanks.

Thanks, Sean. So I think what we said in the last number of calls, and I don't recall if I just said it in my prepared remarks a little bit ago, but I think maybe in my prepared remarks this time around, I talked about health care and packaging kind of strong double-digit growth. And I think, in the past number of calls, I called out kind of a 20% to 25% annual growth rate from, say, '16 to '19 or '20. I didn't exclude those numbers on purpose. I mean, I still think 20% to 25% CAGR to healthcare and packaging is where we're at, certainly, through '19 and potentially '20. Sean, we intentionally don't break out healthcare and packaging at the moment for a variety of reasons. I do think that one of the things I've been talking to Forbes and Beth and Adam about is the last time we did do an Investor Day was coming up on, call it, /18 months ago. I think that there's just a lot of good stuff going on in the company. And we're giving thought to putting together another Investor Day. Let's see if we pull that together, and if we do, I think at that point in time, we'll add a little bit more color around healthcare and packaging. But again, today, we don't break that out.

Okay. Nice job on the overall diversification by the way within DMS. Just want to switch over to EMS and for the follow-up question. The efforts that you have underway that are driving the step-up in growth, you laid out a number of different market segments. There are a fair number of them. And it was surprising to hear such a material, I guess, up-shift in the growth expectations for EMS one quarter to the next, particularly given where the magnitude of revenues are that you are already doing today. So just trying to understand a little bit better. How did that materialize so quickly? How do we think about then what's been called from the opportunity set? And what also might remain in terms of bringing in new business as we progress through the year? I don't know if there's anything that's really been kind of pulled forward here, what have you. Just trying to understand that dynamic because, I think, it's a pretty big step.

Yeah. I'm a little embarrassed by it because, on one hand, I'm pounding the drum with Forbes on we're driving for a less volatility, more predictability, and we are. And I do think, if you just watch this play out for the next couple years, that's what you'll see. It's a little bit surprising to us, and it's really all around acceleration of stuff that we thought might happen in the back half of the year. We're a little bit suspect of it. I thought it might go into '19. And so it's stuff that's been on our radar. It's stuff that, in terms of wins, hit heavier than we thought might in terms of total wins. So it's acceleration. And I kind of scratch my head and say, ' you know what, our structure, our solution-based approach, one of the things the team has done is they - that's approaching a $12 billion business for us. And one of the things the leadership team has done there is they've kept that $12 billion of business really broken up in appropriate smaller bites. And those individual teams really have pulled together wonderful domain expertise, and they've just gone after these markets in a way that's different than we have in the past. And again, touch wood with our scale and all of our solutions, it seems to be working. So I'll take it while we can get it.

Sean, if I may add. Mark referenced earlier some of the smaller tuck-in acquisitions that we've done. And I think those are really starting to bear fruit for us. And allowing our EMS teams to sell and engage customers in higher value-add content and engineering. And we've been very deliberate over the last 24 months about where we're looking and quite rebuilding those capabilities across the company.

Well, it's great. Congratulations. Thanks very much for the color, folks.

Thanks, Sean.

Our next question comes from the line of Sherri Scribner [Deutsche Bank]. Your line is open.

Hi. Thanks. A lot of my questions have been answered, but I was hoping to get a little more detail on the model, Forbes. If you look at the interest expense line, it ticked up. Can you give us some sense of where you think that number should be given the changes that you made to your debt structure? And then thinking about the tax rate, 28% seems higher than what you've guided to before. What type of tax rate should we think about on a go-forward basis? Thanks.

Yes, of course. This past quarter, you're absolutely correct, the interest rate was higher. This quarter, what was also included in there was, I think, it was about $2.5 million with associated with essentially prepaying our bonds, as we swapped those bonds out. So that's a onetime negative event, if you will, to the interest rate there. So as we go forward, I'd model $38 million to $39 million a quarter, which is where we've typically been running. And then on the tax rate, next quarter, a little bit higher than we've been seeing and that's just based on the mix of earnings. We have some tax-advantaged structures in Asia, and obviously, that's an investment quarter for us in Q3 as we ramp within our Green Point operations. Hence, we start to see little bit higher tax rates in the third fiscal quarter, and that should attenuate a little bit as we work through the end of the year. For fiscal '19, we'll see where that lands, but I'd suggest modeling at 26 type rate for the full fiscal year at this point in time.

Okay, great. And then just the distressed customer charge that you saw this quarter. Can you give us more detail? And is that something that you expect to be ongoing? Or is that just this quarter? Thanks.

Yes, that's a onetime event. That's associated with disengagement with Jawbone [ph] So yes, we shouldn't see anything else attributed to that.

Thank you.

Our next question comes from the line of Ruplu Bhattacharya [Bank of America Merrill Lynch]. Your line is open.

Hi. Thanks for taking my questions and congrats on the quarter. Mark, typically, the third quarter is an investment quarter for the mobility segment, and then you have ramps in the third and the fourth quarter. Do you think this year your investments and the ramp can be easier for you than you've had in prior years, and the investment can be lower than what you've had to do in prior years?

You know, what, you're really, really knowledgeable in the areas where we tend to do a lot of technical ramps in 3Q, and none of them are ever easy. So I wish they were. But I think, again, some of the financial impact, if you look at - I don't know, if I just use rough numbers, I think last 3Q in DMS, we broke about even at a DMS line level. If you assume and the revenue we gave you in the slide deck today that - let's assume EMS is about the same margin structure as it was in 3Q of '17, you're back into some decent profits on a relative basis for the third quarter. If you go back to the 3Q of '16, if I remember right, I think we lost money at an enterprise level for DMS in '16. We broke about even last year. But I think we'll make some good profits this year, and I think some that's a sign of healthcare packaging and then general diversification within Green Point. But the task at hand, the investments that we're making, especially around the mobility sector, are still pretty challenging. And I look forward to seeing how we do because it's a good business for us.

Okay. Okay, that's helpful. And thanks for the color on that. And then just on the EMS side. So it looks like, like you said, I mean, for the full year, you'll probably grow double of what you have thought, maybe 7% year-on-year. How should we think about that going forward into fiscal /19 and '20? I mean, you're seeing strength in so many different end markets, but is that sustainable into the next couple of years?

We haven't talked much about '19. If I had to flip a coin right now, I'd say, the top line, that's not sustainable. I think that you have things where the stars align. And to think we can take a $12 billion EMS business and grow it at 6%, 7%, 8% year-on-year, I doubt that's going to happen But boy, oh, boy, am I pleased with what's in front of us. And we'll see what '19 holds, and maybe we'll talk more about that in the June call.

Okay. Thanks for the color on that. And my last question for Forbes. I mean, if you can just give us some color on free cash flow for this year and next year. And in general, it's been a while since you've had a dividend increase. So any thoughts on that? I mean, what would be your preference in terms of M&A versus increasing the dividend versus buyback, so in general, capital allocation preferences?

Yes. And so in terms of free cash flows, I stand by what we talked about in our Analyst Day of late '16. So over that '16, '17 - excuse me, '17, '18 and '19, generating $3.5 billion of operational cash flow. I think we're firmly on track there. CapEx of about $1.8 billion. So $1.7 billion of free cash flows. We committed to return $1 billion through capital allocation through '18 again firmly on track. So as Mark answered to an earlier question, we'll continue to work through our thinking then. Our acquisitions, as Mark noted, are tuck-in nature. I'd like that approach. We're seeing growth as a result, engineering capability. So as we move forward, we'll take a look at that. In terms of dividend specifically, I think for anything meaningful there, it'd be a significant move-up. And certainly, I am more of a preference of stock repurchases back. And I think our cash flows could certainly continue to support a capital allocation policy, but more on that in the second half of fiscal year.

Yes, maybe I could comment. On the one thing I'd like about what we're doing at the moment is, A, I think it's very reflective of the strength of cash flows because we're able to run the business in, I think, a very prudent way. We're able to give some money back to shareholders. And again, if nothing crash and burns in front of us, the outlook is quite good. So right now, I guess, leaning more towards the share buybacks based on where the share price is. And the other, you get a bit of a benefit there because if hypothetically, we like the way the future looks, it's a good time to lean into the buybacks. And at some point in time, if the share price were to normalize, maybe align with how we think the business is going to turn out the next couple of years, then maybe we lean back into the dividend. But the nice thing is at that point in time, we'd be paying a dividends on less shares. So I think, all around, I like our approach with what we're doing in M&A. I like our approach with organic investments. And at this point in time, I have a preference towards the share buybacks.

Okay. Thanks for all the details. And congrats again on the quarter and the guide.

Thank you.

Thank you. Operator Our next question comes from the line of Jim Suva [Citi]. Your line is open.

Great. Thank you very much. It's Jim Suva from Citi. On the CapEx for this year, is it still on the same dollar amount, but importantly being spent in the same direction? The reason why I asked is - or allocation. The reason I asked is it sounds like your packaging business is really getting better strength than anticipated. And as we look ahead, should we start to build in some more support from CapEx in that allocation? Or how should we think about that? Thank you.

Thanks, Jim. I think what we said, either Forbes I or both of us as we came into the year, the CapEx would be about 700. I think that number still feels about right. And I think, in general, our CapEx today that we're spending is probably as equally spread and diversified across the business than it's ever been. So I don't know if that's where you're going with a question. Certainly, packaging and healthcare are part of that, as well as a number of various in EMS. And I think on the EMS side, the revenue would reflect that. And on the healthcare and packaging side, if they're growing at 20%, 25% they need a bit of capital as well.

Yes, that's exactly the answer to the question. And then my follow-on, though, is with that strength in both your new program or wins of EMS and your packaging strength you're seeing, do we need to start to earmark some more money to support those or your current plans can support that growth for the foreseeable future?

I'll answer it in two parts. Number one is I think the 700 is good for this year. We haven't talked about CapEx for next year yet, so we'll get to that later in the year. In terms of the makeup of CapEx, if I go back to, say, fiscal '15 or '16, I think a large percentage of our CapEx at that point in time and maybe even as far back as '14 was concentrated around maybe single programs. Today, if you were to prioritize [ph] the CapEx for '17, and I imagine the same will hold true for this year and '19, you'd see a fairly equally spread, widespread spread pareto [ph] of the CapEx. So the CapEx makeup today and next year looking much different than it did maybe back in fiscal '14, '15 and even '16.

Great. Thanks so much for the details and clarifications. It's greatly appreciated. Thank you.

Yeah. Thanks, Jim.

Our next question comes from the line of Steve Milunovich [ph] Your line is open.

Hi. This is Thejes [ph] on for Steve Milunovich. I was hoping you could talk a little bit more about the new program wins in EMS. You mentioned winning in markets that aren't necessarily growing. I guess, optical fits into that. I was hoping you could give a little bit more color on that. And second, one of your competitors has been saying that medical companies are outsourcing less. Is that something you're seeing?

So maybe I misspoke. I don't think I said that our wins in EMS were solely in markets that weren't growing. I think maybe I gave a two-part response to an earlier question. One part of my response is we absolutely are seeing strength in EMS and new program wins in areas of the market that are growing. But then we do have the benefit of - in maybe areas of or end markets that we serve in our EMS business that might not be growing or flat, we're fortune enough to pick up share. So again, when I look at the pareto [ph] and the makeup of the increase in revenue from '17 to '18, pretty broad based and it's kind of what I would expect based on our approach for that business.

And on medical? Are you seeing them outsource less?

We've not seen much of a change in terms of medical outsourcing one way or the other.

Thank you.

Yeah. You're welcome.

[Operator Instructions] We have a question from the line of [indiscernible] Your line is open.

Hi. Thanks for taking my question Just one about the long-term DMS margin targeted range of 5% to 7%. I guess, how should we think about it? Is there a target revenue rate above which you think the segment would be in that 5% to 7% range or maybe a mix of mobility versus non-mobility?

So I am still hell-bound on getting our DMS margins to the 5% range. And I know I've been banging on the drum on that for a couple of years. I think what we're doing in terms of serving all the different markets in that market quite well. I'm still confident we're going to get there. So I think I don't remember when I said it. But I think I said either in the June call or the September call, I said something about - I thought we'd get to the 5% range the first half of '18. I think we missed that by, I don't know, $10 million, $12 million, and never thought we'd get there for the whole year. But I still think the 5% to 7% range long-term for DMS is something that we're shooting for.

Got it. Thank you. And on your CapEx of $700 million, how much of that would you say is maintenance versus expansionary?

Maintenance, roughly 250, something on 250, 300.

Got it. Thank you so much for the color.

You're welcome.

There are no further questions at this time. Presenters, you may continue.

Thank you very much for everyone for joining us today for our fiscal Q2 results. Please feel free to reach out to us with any follow-up questions that you may have. And now we'll let everyone get back to watch madness. Thank you.

This concludes today's conference call. You may now disconnect.